DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.compose your message
message sent
email sent successfully
Trusted Resources: News & Events
Latest announcements and gatherings
Novel Sickle Cell Drug Causes Radical Results in End of Life Patients
This week the FDA approved a novel treatment for sickle cell disease, a serious and sometimes deadly disease that affects around 100,000 Americans. The treatment was found to exceptionally improve the health and quality of life in the “end of life” patients involved in the trials, and experts believe that upon release, it may do much to improve the lives of sickle cell patients throughout the world.
Oxbryta is an inhibitor of deoxygenated sickle hemoglobin polymerization and was granted Accelerated Approval. This classification allows the FDA to quickly approve drugs for serious conditions. The drug’s trial consisted of 274 patients with sickle cell disease who received different doses of the medication or a placebo, a press release explained.
Results showed that the medication was able to increase the hemoglobin response rate in patients far more than those in the placebo group. This is important as sickle cell affects the hemoglobin, a type of red blood cell, and leads to some of the disease’s devastating effects.
Related Content
-
education & researchHigh mortality among children with sickle cell anemia and overt stroke who discontinue blood transfusion after trans...BACKGROUND: Chronic blood transfusion is...
-
news & eventsTeen with sickle cell disease takes class trip to Europe with Loyola Medicine’s helpAnyah Randolph, a teenager with sickle c...
-
education & researchPredictors of acute care utilization and acute pain treatment outcomes in adults with sickle cell disease: The role ...Despite its rarity in the United States,...
-
Community Center3 Gene Editing Approaches for Sickle Cell DiseaseSickle cell disease (SCD) is a perfect c...
-
news & eventsPhase 1 trial to test under-the-skin injection of sevuparin in sickle cell patientsModus Therapeutics is going to launch ...
-
Community CenterLiving With Sickle Cell Disease: One Person’s Story of Pain and Prejudice and Their Hopes for a Stem Cell TherapyMy name is Marissa Cors, I have sickle c...
-
videos & visualsTeen is one of the first ever to get his genes editedhttps://www.youtube.com/watch?v=0xv0CBuj...
send a message
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.